miR-181a/b downregulation exerts a protective action on mitochondrial disease models

Area of Science:

• Biochemistry
• Genetics
• Neuroscience

Background:

• Mitochondrial diseases (MDs) stem from impaired oxidative phosphorylation, leading to severe, often fatal, conditions.
• Current therapies for MDs are limited, highlighting the need for novel treatment strategies.
• Mitochondrial dysfunction is implicated in various neurodegenerative disorders.

Purpose of the Study:

• To investigate the role of microRNAs miR-181a and miR-181b (miR-181a/b) in regulating mitochondrial biogenesis and function.
• To explore the therapeutic potential of miR-181a/b downregulation in animal models of MDs.

Main Methods:

• Assessed the impact of miR-181a/b on genes controlling mitochondrial biogenesis and function.
• Examined the effects of miR-181a/b inactivation on mitochondrial turnover in retinal cells.
• Evaluated miR-181a/b downregulation in animal models of microphthalmia with linear skin lesions and Leber's hereditary optic neuropathy.

Main Results:

• Downregulation of miR-181a/b was found to enhance mitochondrial turnover in the retina.
• This downregulation promoted coordinated activation of mitochondrial biogenesis and mitophagy.
• miR-181a/b inactivation demonstrated significant neuroprotective effects in tested MD models, ameliorating disease phenotypes.

Conclusions:

• miR-181a/b play a crucial role in maintaining mitochondrial homeostasis.
• Targeting miR-181a/b represents a promising gene-independent therapeutic strategy for MDs involving neuronal degeneration.
• These findings open new avenues for treating mitochondrial diseases affecting the nervous system.